Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

KPasithea Therapeutics Corp.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
K

Pasithea Therapeutics Corp.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
    Sep 14, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
    Sep 3, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
    Jul 21, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
    Jul 8, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
    Jun 30, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
    Jun 16, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
    Jun 15, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
    Jun 2, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
    May 4, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
    Apr 20, 2026Pasithea Therapeutics Corp. (KTTA) Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$0.51Close · Sep 22, 2026